TY  - CHAP
M1  - Book, Section
TI  - Epilepsy
A1  - Nguyen, Viet-Huong V.
A1  - Baca, Christine B.
A1  - Chen, Jack J.
A1  - Rogers, Susan J.
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
PY  - 2017
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - Content  UpdateJan.  10,  2018Newly  Approved  Medications  for  Lennox-Gastaut  and  Dravet  Syndromes:  The  U.S.  FDA  approved  two  new  medications  for  additional  seizure  control  in  patients  who  are  resistant  to  standard  therapies  alone.  Cannabidiol  (Epidiolex)  was  approved  as  an  adjunctive  treatment  for  seizures  related  to  Dravet  and  Lennox-Gastaut  Syndromes  and  stiripentol  (Diacomit)  is  indicated  for  patients  with  Dravet  Syndrome  who  are  also  taking  clobazam.  Both  medications  have  proven  to  be  effective  in  decreasing  the  percentage  of  drop  seizures  over  a  trial  period  compared  to  placebo.  Though  these  medications  appear  effective,  the  true  long-term  impact  cannot  be  accurately  assessed  with  the  data  presented.  Both  of  these  drugs  will  be  available  in  the  United  States  over  the  course  of  2019.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/16
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1161501483
ER  -